Condition-specific portfolio showcases cannabis industry first-to-market milestones, including clinically measured bioavailability and science-backed cannabinoid and terpene ratios.


News provided by

Geocann

May 06, 2019, 14:24 ET

FORT COLLINS, Colo., May 6, 2019 /PRNewswire/ -- Geocann is proud to announce that the company has successfully commercialized the first formulation in a robust portfolio of CBD soft gel products that utilize the multi-patented VESIsorb® delivery system for optimal absorption and measured bioavailability. The formulation is loaded with a science-backed two-to-one ratio of CBD to BCP (beta-caryophyllene) which has been shown to have a synergistic effect as agonists for the CB2, 5-HT1A and glycine receptors.

Screenshot 2019 06 26 at 13.03.18

Geocann has worldwide exclusivity for cannabinoids formulated with VESIsorb®, and the company is quickly partnering with strategic brand leaders in key channels of distribution to deliver its robust portfolio of patent-protected products.

"This product launch signifies substantial first-to-market milestones for the cannabis industry and further advances Geocann's leadership position to combine clinically-researched cannabinoids with technologically-advanced innovations that differentiate our formulations with superior therapeutic performance and unmatched supporting science," said Jesse Lopez, CEO and founder.

The company has developed an impressive vertically integrated system that ensures product quality and consumer safety through rigorously tested starting materials that are formulated with VESIsorb® to optimize the performance of the key actives with dramatically improved absorption and bioavailability.

"It is well-known that hemp oil is poorly absorbed in the body," said Marc Weder, Chief Scientific Officer. "Formulations utilizing VESIsorb® ensure that health conscious consumers receive the maximum benefits from key cannabinoids and terpenes, like CBD and BCP. Better absorption leads to higher plasma concentration levels and allows the body to use more of these active ingredients."

Geocann has worldwide exclusivity for cannabinoids formulated with VESIsorb®, and the company is quickly partnering with strategic brand leaders in key channels of distribution to deliver its robust portfolio of patent-protected products, including the recent entry into the European marketplace through Germany.

"We are proud to be the first to deliver a precise and consistent solid dosage form of CBD formulated in a patented delivery system with a 30-year history of safe and effective use. As the consumer demand for bio-enhanced cannabinoid products continues to grow, Geocann is supremely positioned to be the industry's premier choice for the safest and most efficacious product solutions," said Lopez.

For more information and interview requests, please contact Sam Davidson at 970-657-2479 or This email address is being protected from spambots. You need JavaScript enabled to view it..

SOURCE Geocann

READ FULL ARTICLE HERE

CHEWING GUM COMPOSITION CANNABINOIDS & OPIOID AGONISTS / ANTAGANISTS

26 Jun 2019

READ FULL ARTICLE HERE  

NASAL CANNABIDIOL COMPOSITIONS - INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT

26 Jun 2019

Related Applications [0001] This application...

Medlab Clinical on track for analytical release of Nanabis pain management medicine

26 Jun 2019

02 Mar 2018Medlab Clinical on track for...

Geocann Launches Cannabidiol (CBD) Soft Gel Formulations Utilizing Patented Drug Delivery Technology

26 Jun 2019

Condition-specific portfolio showcases...

Afriplex Gears Up For SA’s Cannabis Explosion

17 Apr 2019

Afriplex, the Paarl-based botanicals ingredient...

ASTM International and ICCI Sign MOU on Cannabis Standards

12 Dec 2018

ASTM International and the International...